Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Orchid Pharma reports positive EBIDTA in Q2

The company is focussed on increasing the capacity utilizations while controlling costs

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore

Alembic receives USFDA final approval for Cyclophosphamide Capsules

Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.